Bid for Allergan: Morgan Stanley gets a bitter pill
Pharma firm uses bankers' emails to put further pressure on Valeant
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
[NEW YORK] In its quest to defend against a US$53 billion hostile takeover, Allergan pulled back the veil on the usually secretive world of mergers and acquisitions banking on Monday.
Reiterating its belief that the business model of Valeant Pharmaceuticals is unsustainable, Botox-maker Allergan took the unusual step of publishing excerpts from emails written by senior investment bankers that it says bolsters its case.
Morgan Stanley is now advising Valeant, according to people briefed on the matter. But before it began working for Valeant, Morgan Stanley tried to get hired by Allergan.
Share with us your feedback on BT's products and services
TRENDING NOW
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Beijing’s calculated silence on the Iran war
DPM Gan warns of 3 structural shifts to the global system that will bring greater challenges – and opportunities
